Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Soligenix Inc 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 USA

www.soligenix.com Employees: 15 P: 609-538-8200 F: 609-452-6467

Description:

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ' (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 7,403
Enterprise Value, $K 1,203
Shares Outstanding, K 2,510
Annual Sales, $ 840 K
Annual Net Income, $ -6,140 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,640 K
EBIT, $ -7,780 K
EBITDA, $ -7,760 K
60-Month Beta 1.79
% of Insider Shareholders 2.80%
% of Institutional Shareholders 3.60%
Float, K 2,439
% Float 97.20%
Short Volume Ratio 0.42

Growth:

1-Year Return -67.42%
3-Year Return -98.40%
5-Year Return -99.13%
5-Year Revenue Growth -83.97%
5-Year Earnings Growth 92.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.78 on 11/08/24
Next Earnings Date 11/11/24
Earnings Per Share ttm -9.31
EPS Growth vs. Prev Qtr 40.46%
EPS Growth vs. Prev Year 69.53%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-16 on 06/06/24

SNGX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -223.29%
Return-on-Assets % -74.18%
Profit Margin % -730.95%
Debt/Equity 0.79
Price/Sales 9.21
Price/Cash Flow N/A
Price/Book 1.18
Book Value/Share 1.52
Interest Coverage -157.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar